RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Neurofibromatosis Type 1: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Intelligence Over Time in Children with Neurofibromatosis Type 1 Based on a Structured Natural History-Study.
van Abeelen Sandra et al., Journal of child neurology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41700776/
- 2.
Associations between sleep disturbance, sleep-related impairment, and attention and learning disorders in youth with NF1.
Walsh Karin S et al., Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41944082/
- 3.
Phenotype of neurofibromatosis 1: A comparison study between NF1 mutant mice and humans.
Fertitta Laura et al., The Journal of investigative dermatology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42067126/
- 4.
Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review.
Román-Mendoza Nelly Marlene et al., International journal of surgical pathology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42135588/
- 5.
Screening for neurofibromatosis type 1-related optic pathway gliomas: a systematic review.
Alshehri Abdullrahman et al., Canadian journal of ophthalmology. Journal canadien d'ophtalmologie (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42150614/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
NCT06961565 · Recruiting · Phase 1 · Pasithea Therapeutics Corp.
Ages 18 and over
https://clinicaltrials.gov/study/NCT06961565
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Neurofibromatosis Type 1
Neurofibromatosis type 1 is a genetic condition that causes tumours called neurofibromas to grow on nerves, along with skin markings and other features. It affects about 1 in 3,000 people. New targeted therapies (MEK inhibitors) have recently been approved for treating associated tumours, marking a significant advance in care.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
This study examines the course of intelligence in children with neurofibromatosis type 1 (NF1) and factors influencing changes. In this cross-sectional and longitudinal study, 397 children were assessed at ages 3, 6, 11, and 15 years using a neuropsychological test battery. Comparisons of demographics and scores were conducted across and within cross-sectional and longitudinal groups. Cross-sectionally, 15-year-olds outperformed 11-year-olds on Performance IQ (PIQ). A reduced PIQ at age 11 years was found that appeared to recover by age 15 years in the longitudinal group. The mother's level of education, the mode of inheritance, or attention-deficit hyperactivity disorder were not predictive of these changes. Overall, intelligence remains stable in children with NF1 between 3 and 15 years of age. The gap between PIQ and VIQ decreases over time. Neurocognitive monitoring is recommended during the critical period between ages 6 and 11 years due to risks of attention and learning issues.
Common Questions
What is Neurofibromatosis Type 1?
Neurofibromatosis type 1 is a genetic condition that causes tumours called neurofibromas to grow on nerves, along with skin markings and other features. It affects about 1 in 3,000 people. New targeted therapies (MEK inhibitors) have recently been approved for treating associated tumours, marking a significant advance in care.
How many clinical trials are available for Neurofibromatosis Type 1?
RareWays currently indexes 122 clinical trials for Neurofibromatosis Type 1, of which 20 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Neurofibromatosis Type 1 come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Neurofibromatosis Type 1.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.